share_log

Chardan Capital Maintains Buy on Gain Therapeutics, Maintains $6 Price Target

Benzinga ·  Aug 10 05:16  · Ratings

Chardan Capital analyst Keay Nakae maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment